{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'Section 13.7.2.7 Concomitant Medications', 'Concomitant medications will be coded using the World', 'Health Organization Drug Dictionary and will be', 'summarized by Anatomic Therapeutic Chemical', 'Classification System 3 level 2 (therapeutic level), level 4', '(generic level), and standard preferred names. Both prior', 'and concomitant medications will be included in by-', 'patient data listings.', 'Confidential', 'Page 138', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Amendment 2, Version 3.0', 'Amendment Rationale', 'The primary purpose for this amendment is to incorporate changes the statistical analysis', 'sections to address comments from the FDA received on 04 April 2017.', 'Other changes include:', 'Additional pregnancy testing and a clarification to contraception requirements to', 'align with the recommendations of the Clinical Trial Facilitation Group', 'Details for continuation of study treatment for patients if the study is terminated early', 'to comply with ICH GCP E6', 'The revised protocol Version 3.0 dated 06 April 2017 will be submitted by the Principal', 'Investigator(s) to all applicable Institutional Review Boards, Independent Ethics Committees, or', 'Research Ethics Boards, and by Karyopharm Therapeutics Inc. to all applicable regulatory', 'authorities.', 'A summary of the changes that were made to Version 2.0 of the protocol in Version 3.0 is', 'provided below.', 'Changes to the protocol', 'Administrative', 'Updated the version number and date to Version 3.0 and 06 April 2017 throughout to', 'reflect the changes made in this version (Modified sections: Global).', 'Revised \"> Grade X\" to \"Grade > X\" and \">> Grade X\" to \"Grade > X\" (Modified', 'sections: Global).', 'Revised the first signatory to the Chief Executive Officer and Acting Chief Medical', 'Officer (Modified section: Signature Page).', 'Made minor editorial changes to the supportive care table (Modified section:', 'Table 15).', 'Randomization', 'Added details for the Interactive Response Technology system that will be used to', 'perform treatment randomization to address the FDA request to include a', 'randomization method in the protocol (Modified section: 8.2).', 'Early Termination of the Study', 'Added details for continuation of study treatment for patients if the study is', 'terminated early to comply with ICH GCP E6 (Modified section: Section 9.1).', 'Contraception Requirements', 'Clarified that double-barrier contraception methods are considered effective but not', 'highly effective to align with the recommendations of the Clinical Trial Facilitation', 'Group. Revised text: \"A combination of male condom with either cap, diaphragm or', 'sponge with spermicide (double barrier methods) are also considered acceptable (ie,', 'Confidential', 'Page 139', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'effective), but not highly effective, birth control methods.\" Also clarified that sexual', 'partners who are surgically sterilized are not exempt from the contraception', 'requirements unless they are \"permanently\" surgically sterilized (Modified section:', 'Section 10.8.1).', 'Schedule of Assessments', 'Added the requirement for pregnancy testing (serum hCG or urine) for females of', 'childbearing potential prior to dosing on Day 1 of Cycles >2 to align with the', 'recommendations of the Clinical Trial Facilitation Group (Modified sections:', 'Section 11.5.2.2 and Tables 2 and 12).', 'Efficacy Analysis', 'For the PFS primary efficacy endpoint, changed the analysis to stratified log-rank test', 'and stratified Cox model (previously in Version 1.0 of the protocol) to address the', 'FDA request to explain why the stratification factors were removed. Also, specified', 'that the stratified log-rank test will be used for the secondary analyses of OS, DOR,', 'and OS1', 'CCI', 'will be', 'performed using stratified log-rank test (Modified sections: Sections 13.5.1.1, 13.5.2,', 'and 13.5.3).', 'For the ORR efficacy analysis, specified that patients missing post-C1D1 MM disease', 'assessments will be imputed as non-responders to address the FDA comment that', 'patients missing ORR assessment should be imputed as non-responders (Modified', 'section: Section 13.5.1.2).', 'Changed the timing of the secondary analyses from \"after significance is reached for', 'PFS\" to \"at the time of ORR analysis\" and specified that \"statistical significance of', 'secondary endpoints will not be claimed until ORR and PFS have reached', 'significance.\" This change was made to address the FDA request to specify how the', 'alpha will be allocated for the secondary endpoint if the ORR result is significant, but', 'the PFS secondary interim analysis result does not cross the boundary (Modified', 'section: Section 13.5.2).', 'Confidential', 'Page 140', 'Version 4.0']\n\n###\n\n", "completion": "END"}